Geode Capital Management
CBIO

Geode Capital Management’s Crescent Biopharma CBIO Stock Holding History

Geode Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.92M Buy
384,576
+280,355
+269% +$5.47M ﹤0.01% 2737
2026
Q1 		$1.92M Buy
104,221
+13,142
+14% +$151K ﹤0.01% 3141
2025
Q4 		$1.08M Buy
91,079
+21,945
+32% +$280K ﹤0.01% 3356
2025
Q3 		$822K Buy
+69,134
New +$917K ﹤0.01% 3449
2025
Q2 		– Sell
-5,717
Closed -$120K – 4474
2025
Q1 		$120K Buy
5,717
+505
+10% +$13.5K ﹤0.01% 3988
2024
Q4 		$130K Hold
5,212
– – ﹤0.01% 4027
2024
Q3 		$88.1K Buy
5,212
+340
+7% +$7.13K ﹤0.01% 4141
2024
Q2 		$137K Sell
4,872
-179
-4% -$18.6K ﹤0.01% 4037
2024
Q1 		$1.52M Buy
5,051
+262
+5% +$78.3K ﹤0.01% 3218
2023
Q4 		$1.13M Buy
4,789
+191
+4% +$29.7K ﹤0.01% 3309
2023
Q3 		$690K Sell
4,598
-164
-3% -$25.9K ﹤0.01% 3480
2023
Q2 		$829K Buy
4,762
+709
+17% +$119K ﹤0.01% 3428
2023
Q1 		$511K Hold
4,053
– – ﹤0.01% 3638
2022
Q4 		$1.23M Buy
4,053
+469
+13% +$69.1K ﹤0.01% 3262
2022
Q3 		$197K Hold
3,584
– – ﹤0.01% 4220
2022
Q2 		$214K Sell
3,584
-50
-1% -$3.7K ﹤0.01% 4215
2022
Q1 		$414K Sell
3,634
-17
-0.5% -$2K ﹤0.01% 4036
2021
Q4 		$525K Sell
3,651
-12
-0.3% -$2.18K ﹤0.01% 4018
2021
Q3 		$802K Buy
3,663
+136
+4% +$28.8K ﹤0.01% 3803
2021
Q2 		$818K Sell
3,527
-3,675
-51% -$935K ﹤0.01% 3706
2021
Q1 		$2.17M Buy
7,202
+473
+7% +$169K ﹤0.01% 3220
2020
Q4 		$2.53M Buy
6,729
+680
+11% +$238K ﹤0.01% 2952
2020
Q3 		$1.86M Buy
6,049
+655
+12% +$250K ﹤0.01% 2914
2020
Q2 		$2.03M Buy
5,394
+220
+4% +$62.3K ﹤0.01% 2828
2020
Q1 		$1.18M Buy
5,174
+270
+6% +$103K ﹤0.01% 2945
2019
Q4 		$2.59M Sell
4,904
-139
-3% -$75.2K ﹤0.01% 2846
2019
Q3 		$2.17M Buy
5,043
+370
+8% +$238K ﹤0.01% 2900
2019
Q2 		$5.57M Buy
4,673
+222
+5% +$265K ﹤0.01% 2319
2019
Q1 		$5.54M Buy
4,451
+331
+8% +$379K ﹤0.01% 2267
2018
Q4 		$3.9M Buy
4,120
+574
+16% +$691K ﹤0.01% 2372
2018
Q3 		$5.11M Buy
3,546
+293
+9% +$443K ﹤0.01% 2346
2018
Q2 		$5.25M Buy
3,253
+1,239
+62% +$2.13M ﹤0.01% 2297
2018
Q1 		$3.27M Buy
2,014
+444
+28% +$923K ﹤0.01% 2497
2017
Q4 		$2.63M Hold
1,570
– – ﹤0.01% 2605
2017
Q3 		$2.19M Buy
1,570
+112
+8% +$131K ﹤0.01% 2686
2017
Q2 		$1.63M Buy
1,458
+508
+53% +$420K ﹤0.01% 2849
2017
Q1 		$515K Hold
950
– – ﹤0.01% 3302
2016
Q4 		$579K Buy
950
+90
+10% +$56.2K ﹤0.01% 3218
2016
Q3 		$615K Buy
860
+40
+5% +$30.6K ﹤0.01% 3169
2016
Q2 		$595K Buy
820
+305
+59% +$210K ﹤0.01% 3150
2016
Q1 		$306 Sell
515
-1
-0.2% -$513 ﹤0.01% 3463
2015
Q4 		$294K Buy
516
+2
+0.4% +$1.33K ﹤0.01% 3518
2015
Q3 		$288K Buy
514
+1
+0.2% +$722 ﹤0.01% 3511
2015
Q2 		$408K Buy
513
+17
+3% +$14.1K ﹤0.01% 3290
2015
Q1 		$412K Buy
496
+20
+4% +$15.5K ﹤0.01% 3272
2014
Q4 		$342K Buy
476
+2
+0.4% +$1.56K ﹤0.01% 3355
2014
Q3 		$329K Buy
474
+90
+23% +$72.8K ﹤0.01% 3353
2014
Q2 		$323K Sell
384
-43
-10% -$42.8K ﹤0.01% 3348
2014
Q1 		$698K Buy
+427
New +$517K ﹤0.01% 2984

Other funds holding CBIO

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $217M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Geode Capital Management's CBIO Position: Q2 2026 in Review

Geode Capital Management increased its Crescent Biopharma (CBIO) stake by 269% in Q2 2026, buying an estimated $5.47M and bringing the position to 384,576 shares worth $6.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2737.

Geode Capital Management first reported a position in CBIO in Q1 2014 and has held it in 49 quarters since. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Geode Capital Management held 384,576 shares of Crescent Biopharma worth $6.92M as of Q2 2026.
  • Geode Capital Management bought 280,355 Crescent Biopharma shares in Q2 2026, an estimated $5.47M.
  • Crescent Biopharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2737 holding.
  • Geode Capital Management first reported a position in Crescent Biopharma in Q1 2014 and has held it in 49 quarters since.
  • 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.